España
Todo parece indicar que estamos ante la repeticion de lo que antes sucedio. Ya hay bastantes acusaciones en lo foros al respecto con un tal Brancaccio que forma parte de a directiva y tiene varios antncedentes
Synergy Shares Climb After Manipulation Arrests
Jun. 4, 2015 7:30 PM ET
Eur/USD
1,127,
rompió soporte en 1.13
leches... yo pensaba que despues de las elecciones cambaria el rumbo, para mi bien que tengo una cuenta con dolores... :)
26 en pre, comienza fuerte. Me esperaba que le metieran algún corto de entrada para tratar de frenarla pero de momento sigue su inercia.Saludos
AMRN
Edito: muchas oscilaciones. Ahora por debajo de 24
futuros no buenos
TSRO
Algo de info sobre la subida a 900mg, no entiendo la implicación exacta pero parece que la mejora no sería mucha en base a datos pasados:
https://twitter.com/biotechinvstr/status/1061965896095272960?s=19
Jeeejem ......MUCHO HABIA DEMORADO
Amarin down 14% premarket on scrutiny of REDUCE-IT study
Nov. 12, 2018 8:51 AM ET|About: Amarin Corporation PLC (AMRN)|By: Douglas W. House, SA News Editor
Amarin (NASDAQ: AMRN) is off 14% premarket on robust volume in apparent reaction to the details of REDUCE-IT, the large-scale study showing the cardiovascular benefits of Vascepa (icosapent ethyl) in statin-treated patients with triglyceride levels between 135 mg/dL and 499 mg/dL, a much larger potential patient population than its current labeling allows.
SA Contributor DoctoRx has published an insightful article on the REDUCE-IT data, including suspicions that the placebo group received mineral oil which could affect the absorption of statins. This "anti-statin" effect could raise "bad cholesterol" levels, enhancing the separation of major adverse cardiac events (MACE) between Vascepa and control.
Previously: Amarin's Vascepa reduced major adverse cardiovascular events by 25% in large-scale REDUCE-IT study (Nov. 11)
ZIOP
Ziopharm up 2% premarket on $50M capital raise and advancement of Ad-RTS-hIL-12
The company has secured $50M in new capital via the direct sale of stock and warrants to a group of investors led by MSD Partners, L.P. The company will issue ~18.9M common shares and warrants to purchase up to the same number of shares at a combined price of $2.64 per share and warrant. The five-year warrants are exercisable at $3.01 per common share. The transaction should close by November 13. Friday's close was $2.51.
Ziopharm Oncology (ZIOP) Announces Immuno-oncology Clinical Supply Agreement with Regeneron to Evaluate Combination Therapy for Patients with Brain Cancer
«Después de nada, o después de todo/ supe que todo no era más que nada.»
